Latest News

• Dr. Saef Izzy’s data shows one-month behavioral outcomes improvement in model of intracerebral hemorrhage (hemorrhagic stroke)
• Modulation of neuroinflammation by inducing FoxP3+ Tregs appears...

• Tiziana planning to advance foralumab, the only fully human anti-CD3 monoclonal antibody, into human testing for hemorrhagic stroke
• Data shows behavioral outcomes improvement at one...

• Data shows reduction of microglia activation and improvement in behavior in rodent model of Alzheimer’s disease (AD)
• Modulation of neuroinflammation may be synergistic to...

Tiziana Life Sciences to Proceed with Phase 2 Clinical Trial in Patients with Non-Active Secondary Progressive Multiple Sclerosis (SPMS)

FDA Provides Positive Feedback on Intranasal Foralumab Program in Patients with Non-Active SPMS

• First Phase 2 trial employing...

March 22, 2023

Nasally Administered Monoclonal Antibody for COVID-19

Emily Harris

Article Information

JAMA. Published online March 22, 2023. doi:10.1001/jama.2023.4000

Treating people with mild to moderate COVID-19 infections nasally with foralumab, an anti-CD3 monoclonal antibody, decreases the expression of genes involved in...

New York, March 22, 2023 – Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, today announces that it has been notified that Gabriele Cerrone, its Chairman...

New York, March 21, 2023 – Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, today announces that it has been notified that Gabriele Cerrone, its Chairman...

New York, March 20, 2023 – Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, today announces that it has been notified that Gabriele Cerrone, its Chairman...

NEW YORK, March 17, 2023 -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announces that it has been notified that Gabriele Cerrone, its...

Article entitled "New T Cell Antibody Treatment Improves Outcomes For Covid Patients" reviews the company's first in class foralumab, a unique Intranasal monoclonal antibody designed to treat multiple sclerosis and a range of other neurodegenerative diseases

NEW YORK, March 17, 2023...